{"id":105160,"date":"2024-09-12T10:19:14","date_gmt":"2024-09-12T08:19:14","guid":{"rendered":"https:\/\/lightweb.dev\/s\/key2compliance\/?p=105160"},"modified":"2024-09-12T13:47:56","modified_gmt":"2024-09-12T11:47:56","slug":"key2compliance-becomes-gba-key2compliance","status":"publish","type":"post","link":"https:\/\/lightweb.dev\/s\/key2compliance\/news\/key2compliance-becomes-gba-key2compliance\/","title":{"rendered":"Key2Compliance becomes GBA Key2Compliance"},"content":{"rendered":"

Press Release <\/span><\/span>\u00a0<\/span>
<\/span>Stockholm, September 12, 2024<\/span><\/span><\/p>\n

Key2Compliance, a leading consultancy and training company serving the Medtech, IVD and Pharmaceutical industries, is now taking the next step in its merger with the GBA Group by changing its name to GBA Key2Compliance.<\/span><\/b>\u00a0<\/span><\/p>\n

Earlier this year, Key2Compliance announced that they had officially become part of the GBA Group. The next phase in this integration is the name change to GBA Key2Compliance.<\/span>\u00a0<\/span><\/p>\n

\u201cThrough the merger with GBA Group<\/a>, we are able to expand our resources and opportunities within our six business areas \u2013 Quality Assurance, Regulatory Affairs, Clinical Development (CRO), Biological Safety and also Training and Courses\u201d, <\/span>says CEO Jan Hellqvist<\/span><\/i>.<\/span>\u00a0<\/span><\/p>\n

\u201cOur customers will continue to work with the same dedicated team, and our procedures and points of contact will remain unchanged. However,<\/span> we are now positioned to serve a broader range of companies\u201d, Jan continues. <\/span><\/p>\n

\u201cAs part of the GBA Group, we can now support our customers in entirely new ways. For our Medical Device clients, in addition to our six business areas, we can now offer product development and engineering services, as well as product testing, distribution, and manufacturing expertise. Meanwhile, our pharmaceutical clients will benefit from expanded services, including in vitro ADME-Toxicology with hepatocytes in the discovery and development phase, regulatory testing, pre-clinical support, central laboratory and clinical trial supply, as well as other analytical services. This makes GBA Group one of Europe\u2019s largest service providers for the Pharmaceutical, IVD, and Medical Device industries,\u201d Jan Hellqvist concludes.<\/span>\u00a0<\/span><\/p>\n

For more information, please contact:<\/strong>
\nJan Hellqvist, CEO<\/span>
\n+46705612519<\/span>
\nJan.hellqvist@key2compliance.com<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

About GBA Key2Compliance<\/span><\/b>
\nGBA Key2Compliance offers complete and optimized solutions in regulatory compliance. Key2Compliance is a full-service partner that offers advice and training for medical devices, in vitro diagnostics, and pharma. GBA Key2Compliance’s areas of competence are medical device QA, pharma QA, clinical development (CRO), biological safety, regulatory issues as well as training and courses.<\/span>
\nwww.key2compliance.com<\/span><\/b><\/a><\/p>\n

About GBA Group<\/span><\/b>
\nGBA Group is an international life science company with over 2,500 employees in 11 countries and a wide range of analysis, logistics and specialist services in pharmaceuticals, medical devices, cosmetics, chemicals, food, drinking water and the environment. The group stands for high technical competence, efficient processes and a focus on customer benefit in operations within research, product development, market development and consumer protection. With its services, GBA Group directly and indirectly makes a sustainable contribution to health, the environment and society.<\/span>
\nwww.gba-group.com<\/span><\/b><\/a>\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Press Release \u00a0Stockholm, September 12, 2024 Key2Compliance, a leading consultancy and training company serving the Medtech, IVD and Pharmaceutical industries, is now taking the next step in its merger with the GBA Group by changing its name to GBA Key2Compliance.\u00a0 Earlier this year, Key2Compliance announced that they had officially become part of the GBA Group. […]<\/p>\n","protected":false},"author":18,"featured_media":105168,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wds_primary_category":21,"footnotes":""},"categories":[21,195],"tags":[338,117,339],"blog-subject":[],"class_list":["post-105160","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-press-release","tag-gba-group","tag-medical-device","tag-pharmaceutical"],"acf":[],"_links":{"self":[{"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/posts\/105160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/users\/18"}],"replies":[{"embeddable":true,"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/comments?post=105160"}],"version-history":[{"count":0,"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/posts\/105160\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/media\/105168"}],"wp:attachment":[{"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/media?parent=105160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/categories?post=105160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/tags?post=105160"},{"taxonomy":"blog-subject","embeddable":true,"href":"https:\/\/lightweb.dev\/s\/key2compliance\/wp-json\/wp\/v2\/blog-subject?post=105160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}